Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost ...
Panelists discuss the considerations guiding treatment choices for lupus nephritis, such as drug interactions, patient characteristics, and steroid use, and how treatment approaches might differ ...
While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious complication of systemic lupus ...